IL2 and autoimmune disease: Therefore, we were inspired to formally evaluate the relationship between Ld-IL2 therapy and infection risk in autoimmune diseases by conducting a retrospective cohort study by comparing the incidence in infection between a large cohort of SLE patients with standard treatment plus Ld-IL2 therapy and a control cohort with standard treatment only.